{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:26:48Z","timestamp":1782890808835,"version":"3.54.5"},"reference-count":43,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T00:00:00Z","timestamp":1323993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Indolent nonfollicular non\u2010Hodgkin B\u2010cell lymphomas (INFLs) are clonal mature B\u2010cell proliferations for which treatment has not been defined to date.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>In this phase 2 study of patients with advanced INFL, the authors evaluated the efficacy and safety of first\u2010line rituximab, fludarabine, and cyclophosphamide (FCR) as induction immunochemotherapy (rituximab 375 mg\/m<jats:sup>2<\/jats:sup> intravenously on day 1 of each cycle and on days 1 and 14 of cycles 4 and 5; fludarabine 25 mg\/m<jats:sup>2<\/jats:sup> intravenously on days 2\u20104, cyclophosphamide 250 mg\/m<jats:sup>2<\/jats:sup> intravenously on Days 2\u20104) every 28 days for 6 cycles followed by a maintenance phase with 4 infusions of rituximab (375 mg\/m<jats:sup>2<\/jats:sup> intravenously on day 1) every 2 months for responders.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Forty\u2010seven patients were enrolled. Among 46 evaluable patients (28 men; median age, 59 years), 19 were diagnosed with lymphoplasmacytic lymphoma, 21 were diagnosed with small lymphocytic lymphoma, and 6 were diagnosed with nodal marginal zone lymphoma. The overall response rate after maintenance was 89.1% with a 67.4% complete remission (CR) rate (CR\/unconfirmed CR) and a 21.7% partial response rate. After a median follow\u2010up of 40.9 months, the failure\u2010free survival and progression\u2010free survival rates both were 90.1%, and the overall survival rate was 97.4%. The main toxicity was hematologic, and related grade 3 and 4 neutropenia was observed in 55.3% of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>FCR induction therapy followed by a short maintenance phase is a highly effective regimen with acceptable toxicity. Cancer 2012. \u00a9 2011 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.26708","type":"journal-article","created":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T10:43:47Z","timestamp":1324032227000},"page":"3954-3961","source":"Crossref","is-referenced-by-count":23,"title":["Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B\u2010cell nonfollicular lymphomas"],"prefix":"10.1002","volume":"118","author":[{"given":"Andrea","family":"Ferrario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pulsoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Olivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Rigacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Stelitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Goldaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Mannina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Gamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,16]]},"reference":[{"key":"e_1_2_8_2_2","volume-title":"World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_8_3_2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.V73.2.579.579","article-title":"Small lymphocytic lymphoma: a clinicopathologic analysis of 268 cases","volume":"73","author":"Ben\u2010Ezra J","year":"1989","journal-title":"Blood."},{"key":"e_1_2_8_4_2","first-page":"198","article-title":"Indolent nonfollicular lymphomas: characteristics, treatment, and outcome","volume":"36","author":"Coiffier B","year":"1999","journal-title":"Semin Hematol."},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802311425"},{"key":"e_1_2_8_6_2","first-page":"104","article-title":"B\u2010chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstrom's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders","volume":"36","author":"Pangalis GA","year":"1999","journal-title":"Semin Hematol."},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2847"},{"key":"e_1_2_8_8_2","first-page":"1883","article-title":"Indolent B\u2010cell non\u2010Hodgkin's lymphomas","volume":"11","author":"Seng JE","year":"1997","journal-title":"Oncology (Williston Park)."},{"key":"e_1_2_8_9_2","first-page":"677","article-title":"Waldenstrom's macroglobulinemia: recent advances in biology and therapy","volume":"7","author":"Neparidze N","year":"2009","journal-title":"Clin Adv Hematol Oncol."},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-174359"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001616917"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.133"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012143432402"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91681-5"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2319"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61125-8"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2395"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.0762"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000077025"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.1.71"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.987"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20234"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-1067-1"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11671"},{"key":"e_1_2_8_25_2","first-page":"114","article-title":"Rituximab (R) maintenance versus observation after short term chemoimmunotherapy R\u2010FND as first line treatment in elderly patients with advanced follicular lymphoma (FL): updated results and safety of the maintenance of an Intergruppo Italiano Linfomi (IIL) randomized trial [ASH Annual Meeting Abstracts]","author":"Vitolo U","year":"2009","journal-title":"Blood."},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk152"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.4556"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140582"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.516"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.015"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.524326"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22740"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21882"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.674"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"issue":"15","key":"e_1_2_8_39_2","article-title":"Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy","volume":"28","author":"Salles GA","year":"2010","journal-title":"J Clin Oncol."},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5827"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07677.x"},{"key":"e_1_2_8_42_2","first-page":"1546","article-title":"Treatment\u2010related myelodysplasia following fludarabine combination chemotherapy","volume":"91","author":"Tam CS","year":"2006","journal-title":"Haematologica."},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.113"},{"key":"e_1_2_8_44_2","first-page":"3580","article-title":"DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4\u2010hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine","volume":"7","author":"Yamauchi T","year":"2001","journal-title":"Clin Cancer Res."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.26708","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.26708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:09:45Z","timestamp":1760281785000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.26708"}},"subtitle":["Phase 2 study of the Italian Lymphoma Foundation"],"short-title":[],"issued":{"date-parts":[[2011,12,16]]},"references-count":43,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2012,8,15]]}},"alternative-id":["10.1002\/cncr.26708"],"URL":"https:\/\/doi.org\/10.1002\/cncr.26708","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,16]]}}}